



new



**chromID**<sup>™</sup>  
by bioMérieux

**VRE**

Chromogenic medium for the rapid & reliable screening  
of acquired Vancomycin resistance Enterococci  
Differentiation and direct Identification of *E. faecium* and *E. faecalis*

**CONTROL VRE SPREAD**

# Isolate VRE Colonies & Start Patient Isolation

*E. faecium* and *E. faecalis* with acquired vancomycin resistance (phenotypes vanA and vanB) are multidrug-resistant organisms which are increasingly responsible for healthcare-associated infections. <sup>(1,2)</sup>

## A Proactive Strategy

- **Resistance transfer from VRE to staphylococci (VRSA VanA) is greatly feared by the medical community.**
- Screening of VRE carriage combined with **rapid** colonized patient **isolation** is the most efficient method of controlling VRE. <sup>(3,4,5)</sup>
- **Reliable differentiation and identification** of *E. faecium* and *E. faecalis* with acquired Vancomycin resistance help effectively **control the spread of VRE.**

Screening of VRE

+ Differentiation & Identification of *E. faecium*, *E. faecalis*


= **High Performance Solution**

## Rapid ↻

chromID™ VRE (patents pending) contains two chromogenic substrates ( $\alpha$ -Glucosidase and  $\beta$ -Galactosidase) and Vancomycin (8mg/l) which enable:

- **Specific** and **selective** isolation and detection of acquired Vancomycin-Resistant enterococci.
  - Direct identification (see protocol) of *E. faecium* and *E. faecalis* after **24 hours** incubation\*\*
  - Characteristic colouration of colonies with:
    - **Bluish-green** colour = *E. faecalis*
    - **Violet** colour = *E. faecium*

\*\* See technical sheet for further information



HAI Offer

Scientific Proofs





## ➔ Simple

- Ready-to-use medium
- Specific chromogenic media for the screening of VRE
- Immediate differentiation of *E. faecium* and *E. faecalis*
- Culture + isolation + identification on the same medium

## ➔ Reliable Selectivity improved

- **The selective mixture inhibits:**
  - enterococci with natural resistance (ie. *E. casseliflavus* & *E. gallinarum*...)
  - most Gram-negative and Gram-positive bacteria as well as yeasts.

ola



Clinician Booklets



**new**

## A Complete, Validated Solution for VRE

**chromID™ VRE**  
Ref. 43004 - 20 plates

**Heart-Brain broth**  
Ref. 42 081 - 20 tubes

## chromID™ Range

### Screening of Multidrug - Resistant Organisms

**new**

**chromID MRSA**  
Ref 43472 - 20 plates  
Ref 43479 - 100 plates  
Ref 43841<sup>(a)</sup> - 20 plates

**chromID MRSA /chromID S.aureus**  
Ref 43466\* - 20 plates

**chromID ESBL**  
Ref 43481 - 20 plates

**new**

### Other Chromogenic Media

**chromID Candida / Sabouraud Gentamicin Chloramphenicol 2 agar**  
Ref 43464 - 20 plates

**chromID C.difficile**  
Ref 43871\* - 20 plates

**chromID Salmonella / Hektoen**  
Ref 43465 - 20 plates

**chromID CPS\***  
Ref 43821\* - 20 plates / Ref 43829\* - 100 plates

**chromID Candida**  
Ref 43631 - 20 plates / Ref 43639 - 100 plates

**chromID CPS\* / Columbia CNA + 5% sheep blood**  
Ref 43473 - 20 plates

**chromID Paeruginosa**  
Ref 43462 - 20 plates

**chromID Salmonella**  
Ref 43621 - 20 plates / Ref 43629 - 100 plates

**chromID S.aureus**  
Ref 43371 - 20 plates

**chromID Strepto B**  
Ref 43461 - 20 plates

**chromID O157H7**  
Ref 42605 - 6x200 mL bottles

**chromID Vibrio**  
Ref 43762 - 20 plates

\* Contact your local bioMérieux representative for availability \*\*consult your local bioMérieux representative for complete list (a) FDA approved - For USA only

### GUIDELINES & REPORTS:

(1) Centers for Disease Control and Prevention. Hospital Infection Control Practices Advisory Committee. Recommendations for Preventing the Spread of Vancomycin Resistance : recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). 2006.

(2) European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2008. EARSS performs on-going surveillance of antimicrobial susceptibility in *Streptococcus pneumoniae*, *Staphylococcus aureus*, *Escherichia coli*, and *Enterococcus faecalis/faecium*. Website at [www.earss.rivm.nl](http://www.earss.rivm.nl).

(3) Muto C.A., J.A. Jernigan, B.E.Ostrowsky, H.M. Richet, W.R. Jarvis, J.M. Boyce, B.R. Farr. 2003. SHEA Guideline for preventing nosocomial transmission of multidrug-resistant strains of *Staphylococcus aureus* and *Enterococcus*. Infect. Control. Hosp. Epidemiol 24:362-386.

(4) Weber S.G., Huang S.S. and co. SHEA/APIC Position Statement / 3, 2007. Legislative Mandates for Use of Active Surveillance Cultures to Screen for Methicillin-Resistant *Staphylococcus aureus* and Vancomycin-Resistant Enterococci: Position Statement From the Joint SHEA and APIC Task Force.

(5) Chamion N. O., Blake R. K., Steed L.L., Salgado C.D. Infection Control and Hospital Epidemiology. May 2008, vol. 29, N°5. Risk of Vancomycin-Resistant *Enterococcus* (VRE) Bloodstream Infection Among Patients Colonized with VRE.

bioMérieux S.A.  
69280 Marcy l'Etoile - France  
Tel.: 33 (0)4 78 87 20 00  
Fax: 33 (0)4 78 87 20 90

[www.biomerieux.com](http://www.biomerieux.com)  
[www.biomerieux-diagnostics.com](http://www.biomerieux-diagnostics.com)

chromID™ VRE is a  marked product